{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-088494","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.282858+00:00","generated_at":"2026-05-19T01:31:42.985344+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455","bullets":["Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.","Net proceeds ~$7.45M; funds for clinical development, working capital, and general corporate purposes.","Mipletamig (CD123xCD3) shows 85% remission rate in evaluable frontline AML patients in RAINIER trial; no CRS in first two cohorts.","Cohort 3 nears full enrollment at highest dose; mipletamig triplet therapy enables transplant in previously ineligible patient.","New preclinical candidate APVO455 (Nectin-4xCD3) added to CD3-targeted pipeline using CRIS-7 domain; targets solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-088494","json":"https://secwatch.observer/filing/0000950170-25-088494.json","markdown":"https://secwatch.observer/filing/0000950170-25-088494.md","text":"https://secwatch.observer/filing/0000950170-25-088494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025088494/0000950170-25-088494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025088494/apvo-20250618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:31:42.985344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}